I know we have covered the HepC trial results from 2024 before, but I am still curious (as I was back then) why BIT did not push forward to a commercial deal at the time.
I seem to recall that BIT wanted too much for the product and another company commercialised a competing product 6 months later.
Could anyone shed any light on what happened? Seems like a colossal lost opportunity.Biotron shares soar on Hepatitis C trial data
Australian drug developer Biotron may have found a potential cure for Hepatitis C, after all patients who completed a trial of its lead antiviral drug emerged with undetectable levels of the virus.
Updated Oct 10, 2014 – 2.59pm,first published at 1.43pmAustralian drug developer Biotron may have found a potential cure for Hepatitis C.
Biotron said on Friday that all patients who completed a phase II clinical trial of its lead antiviral drug, BIT225, had undetectable levels of Hepatitis C after ceasing all treatment.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $210 | 104.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 38848316 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 18281126 | 25 |
View Market Depth
| Last trade - 12.28pm 27/06/2025 (20 minute delay) ? |
| BIT (ASX) Chart |